Abstract
Introduction: The present study has examined microglial and astrocyte activation in association with neuronal degeneration in an animal model using an injection of amyloid-beta peptide Aβ1-42 (Aβ42) plus fibrinogen into rat hippocampus.
Methods: The combination of stimuli is suggested as a novel and potent perturbation to induce gliosis and the production of glial-derived neurotoxic factors in an animal model exhibiting a leaky BBB (blood-brain barrier). Specifically, Aβ42 + fibrinogen stimulation elevated levels of COX-2 (cyclooxygenase-2) and iNOS (inducible nitric oxide synthase) with a considerable extent of neuronal loss associated with microglia and astrocyte activation.
Results: Treatment of injected rats with the broad spectrum anti-inflammatory agent, minocycline or the iNOS inhibitor, 1400 W inhibited gliosis, reduced levels of COX-2 and iNOS, and demonstrated efficacy for neuroprotection.
Conclusion: The findings suggest the utility of combining amyloid beta peptide plus fibrinogen as a potent and understudied neuroinflammatory stimulus for the induction of glial-derived neurotoxic factors in BBB-compromised AD brain.
Keywords: Fibrinogen, amyloid beta peptide Aβ1-42 (Aβ42), Aβ42+fibrinogen injection, microglia, astrocytes, cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), minocycline, 1400 W, neuroinflammation, Alzheimer’s disease (AD).
[http://dx.doi.org/10.1038/nrn3114] [PMID: 22048062]
[http://dx.doi.org/10.1084/jem.20171406] [PMID: 29061693]
[http://dx.doi.org/10.1038/nrneurol.2017.188] [PMID: 29377008]
[http://dx.doi.org/10.1016/j.neuron.2014.12.032] [PMID: 25611508]
[http://dx.doi.org/10.1038/s41591-018-0297-y] [PMID: 30643288]
[http://dx.doi.org/10.1084/jem.20070304] [PMID: 17664291]
[http://dx.doi.org/10.1016/j.neuron.2010.05.014] [PMID: 20547128]
[http://dx.doi.org/10.1111/j.1582-4934.2008.00434.x] [PMID: 18657226]
[http://dx.doi.org/10.1016/j.neurobiolaging.2014.10.030] [PMID: 25475538]
[http://dx.doi.org/10.1016/j.nbd.2007.08.019] [PMID: 17964176]
[http://dx.doi.org/10.1016/j.neuron.2019.01.014] [PMID: 30737131]
[http://dx.doi.org/10.1002/glia.20051] [PMID: 15326618]
[http://dx.doi.org/10.1016/j.expneurol.2005.12.016] [PMID: 16480717]
[http://dx.doi.org/10.1523/JNEUROSCI.2888-08.2009] [PMID: 19129379]
[http://dx.doi.org/10.1186/s12974-015-0339-z] [PMID: 26255110]
[http://dx.doi.org/10.1172/JCI97509] [PMID: 29388925]
[http://dx.doi.org/10.1038/nrn.2018.13] [PMID: 29618808]
[http://dx.doi.org/10.1016/j.neuron.2017.11.021] [PMID: 29216454]
[http://dx.doi.org/10.1096/fj.201800355RRRR] [PMID: 30020833]
[http://dx.doi.org/10.1097/00005072-199911000-00006] [PMID: 10560659]
[http://dx.doi.org/10.1111/j.1538-7836.2009.03438.x] [PMID: 19630789]
[http://dx.doi.org/10.3390/antiox9080743] [PMID: 32823544]
[http://dx.doi.org/10.3390/antiox11010102] [PMID: 35052606]
[http://dx.doi.org/10.1073/pnas.1010373107] [PMID: 21098282]
[http://dx.doi.org/10.1182/blood-2011-11-389668] [PMID: 22238323]
[http://dx.doi.org/10.1038/nature21029] [PMID: 28099414]
[http://dx.doi.org/10.1186/s40478-021-01180-z]
[http://dx.doi.org/10.2174/1567205018666211117100342] [PMID: 34789126]
[http://dx.doi.org/10.1186/1742-2094-8-26] [PMID: 21439035]
[http://dx.doi.org/10.1084/jem.20182042] [PMID: 30459159]
[http://dx.doi.org/10.4061/2011/918280]